(Q33602915)

28 July 2017

Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study (English)

1 reference

28 July 2017

0 references

cardiovascular disease

1 reference

0 references

1 reference

1

Nina Friis-Møller

1 reference

28 July 2017

6

Stephane De Wit

1 reference

Antonella d'Arminio Monforte

28 July 2017

5

object named as

Antonella D'Arminio Monforte

1 reference

28 July 2017

Caroline A Sabin

12

0 references

Jens Lundgren

object named as

Jens D Lundgren

13

0 references

Wafaa El-Sadr

7

object named as

Wafaa El-Sadr

1 reference

28 July 2017

2

Rodolphe Thiébaut

1 reference

28 July 2017

11

Andrew Phillips

1 reference

28 July 2017

10

Ole Kirk

1 reference

28 July 2017

3

Peter Reiss

1 reference

28 July 2017

Rainer Weber

4

1 reference

28 July 2017

Eric Fontas

8

1 reference

28 July 2017

Signe Worm

9

1 reference

28 July 2017

Matthew G Law

14

1 reference

28 July 2017

DAD study group

15

1 reference

28 July 2017

1 October 2010

1 reference

European Journal of Cardiovascular Prevention and Rehabilitation

28 July 2017

1 reference

28 July 2017

17

1 reference

28 July 2017

491-501

1 reference

28 July 2017

5

1 reference

Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men.

28 July 2017

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Class of Antiretroviral Drugs and the Risk of Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

CD4+ count-guided interruption of antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Combination antiretroviral therapy and the risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Cardio- and cerebrovascular events in HIV-infected persons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Cardiovascular disease risk profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Prediction of coronary heart disease: a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Construction and validation of a prognostic model across several studies, with an application in superficial bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Ten-year predicted coronary heart disease risk in HIV-infected men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Changes in biomarkers of cardiovascular risk after a switch to abacavir in HIV-1-infected individuals receiving combination antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Ischemic Heart Disease in HIV-Infected and HIV-Uninfected Individuals: A Population-Based Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Protease inhibitors and cardiovascular outcomes in patients with HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

A Clinically Prognostic Scoring System for Patients Receiving Highly Active Antiretroviral Therapy: Results from the EuroSIDA Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FHJR.0B013E328336A150

10.1097/HJR.0B013E328336A150

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference